A breakthrough treatment to address the unmet medical needs of overweight or obese people under intensive insulin therapy – optimized for administration via insulin pump.
Adocia has developed BioChaperone® LisPram to enable patients affected by both diabetes and overweight or obesity to address weight management and glycemic control as co-primary targets of care.
Today, more and more people are affected by both diabetes and obesity, and “Diabesity” is now considered a pandemic. The two diseases are closely interlinked, one being both cause and consequence of the other. It is therefore crucial to restore the physiologic equilibrium, what can be achieved by BioChaperone® LisPram, a fixed-dose combination of insulin and amylin analogs using the BioChaperone technology.
BioChaperone® LisPram is a ready-to-use co-formulation of pramlintide (amylin analog) and lispro (gold standard mealtime insulin analog). It is designed to be administered via insulin pump, in which it differs from M1Pram, the other Adocia’s insulin-pramlintide combination. BioChaperone® LisPram aims to maintain a good glycemic control, while triggering significant weight loss, associated with effects on satiety and a reduction of the insulin dose.
BioChaperone® LisPram has established a human proof of concept in a Phase 1 study and is available for out-licensing.